Abstract | PURPOSE: MATERIALS AND METHODS: RESULTS: The trial was completed by 21 of 27 patients in the L-arginine group and 25 of 26 in the placebo group. Using per protocol analysis 29% (6 of 21 patients) in the L-arginine group and 8% (2 of 25) in the placebo group were clinically improved by the end of the trial (p = 0.07). A Likert scale showed greater global improvement in the L-arginine group (48%, 10 of 21) compared to the placebo group (24%, 6 of 25) at 3 months (p = 0.05) with a decrease in pain intensity (p = 0.04), and tendency toward improvement in urgency (p = 0.06) and frequency of pain (p = 0.09). Using an intention to treat approach to analysis there were no differences between groups. CONCLUSIONS:
|
Authors | G E Korting, S D Smith, M A Wheeler, R M Weiss, H E Foster Jr |
Journal | The Journal of urology
(J Urol)
Vol. 161
Issue 2
Pg. 558-65
(Feb 1999)
ISSN: 0022-5347 [Print] United States |
PMID | 9915448
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Administration, Oral
- Arginine
(administration & dosage)
- Cystitis, Interstitial
(drug therapy)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Surveys and Questionnaires
|